Inter-patient and intra-tumor radiosensitivity heterogeneity

被引:0
|
作者
Deasy, J [1 ]
机构
[1] Univ Louisville, Henry Vogt Canc Res Inst, Louisville, KY 40292 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To examine possible effects of pretreatment intra-tumor and inter-patient radiosensitivity heterogeneities, and their relation-ships to in vitro SF2 assays and gamma(50) values. Methods: Computer simulations of expected gamma(50) and in vitro SF2 assay results for two different tumor local control models were performed. Both models allow for variation of the intra-tumor radiosensitivity distribution between patients. The first model assumes that intra-tumor radiosensitivity is lognormally distributed, but with variations in the distribution between patients. The second model simulates effects of genomic instability on repair capacity. The most resistant clonogens are assumed to be those which are "genomically undegraded." Results: a) The lognormal model predicts that SF2 CVs of 40% (which are commonly observed) would always lead to very shallow dose-response curves (gamma(50) < 0.7) which are in clear disagreement with the clinically observed slopes (gamma(50) > 2) for some sites in question. The genomic instability model, under certain parameter ranges, predicts that intra-tumor heterogeneity would have a nearly minimal effect on dose-response. With this model, SF2 CVs of 40% could be consistent with steep dose-response curves, in broad agreement with clinical observations for the sites in question. Reported measurement errors in assay reproducibility are much smaller than reported SF, CVs and are unlikely to account for the results. Inclusion of other sources of inter- or intra-tumor heterogeneity only make it more difficult to reconcile modeling results with wide measured SF2 CVs and relatively steep local control curves. Conclusions: The simulation results suggest that reconciling the very wide reported SF2 distributions with fairly steep dose-response curves requires significant intra-tumor radiosensitivity heterogeneity, the extent of which varies between patients. Large variations in SF2 values would then be due to large inter-patient fluctuations in the numbers of the more sensitive clonogens, whereas steep local control curves would be due to smaller inter-patient fluctuations in the radiosensitivity of the most resistant clonogens.
引用
收藏
页码:363 / 381
页数:19
相关论文
共 50 条
  • [21] A population genetics perspective on the determinants of intra-tumor heterogeneity
    Hu, Zheng
    Sun, Ruping
    Curtis, Christina
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2017, 1867 (02): : 109 - 126
  • [22] Simulating the Dynamic Intra-Tumor Heterogeneity and Therapeutic Responses
    Liu, Yongjing
    Feng, Cong
    Zhou, Yincong
    Shao, Xiaotian
    Chen, Ming
    [J]. CANCERS, 2022, 14 (07)
  • [23] Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity
    Bruna R. S. Correa
    Joanna Hu
    Luiz O. F. Penalva
    Richard Schlegel
    David L. Rimm
    Pedro A. F. Galante
    Seema Agarwal
    [J]. Scientific Reports, 8
  • [24] Mutational landscape and intra-tumor heterogeneity of liver cancer
    Fujimoto, Akihiro
    Shiraishi, Yuichi
    Furuta, Mayuko
    Gotoh, Kunihito
    Nakamura, Toru
    Hirano, Satoshi
    Yamamoto, Masakazu
    Yamaue, Hiroki
    Chayama, Kazuaki
    Miyano, Satoru
    Tsunoda, Tatsuhiko
    Nakagawa, Hidewaki
    [J]. GENES & GENETIC SYSTEMS, 2013, 88 (06) : 345 - 345
  • [25] Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity
    Correa, Bruna R. S.
    Hu, Joanna
    Penalva, Luiz O. F.
    Schlegel, Richard
    Rimm, David L.
    Galante, Pedro A. F.
    Agarwal, Seema
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [26] KARYOMETRIC ANALYSIS OF INTRA-TUMOR HETEROGENEITY IN PROSTATE ADENOCARCINOMA
    VANDERPOEL, HG
    MULDERS, PFA
    AALDERS, TW
    OOSTERHOF, GON
    DEBRUYNE, FMJ
    SCHALKEN, JA
    [J]. ANALYTICAL CELLULAR PATHOLOGY, 1994, 7 (02): : 153 - 170
  • [27] Intra-Tumor Genetic Heterogeneity in Metaplastic Breast Carcinomas
    Geyer, Felipe
    Burke, Kathleen A.
    Papanastatiou, Anastasios D.
    Macedo, Gabriel S.
    Brogi, Edi
    Wen, Hannah Y.
    Reis-Filho, Jorge
    Weigelt, Britta
    [J]. MODERN PATHOLOGY, 2017, 30 : 42A - 42A
  • [28] An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity
    Jiang, Shengwei
    Zhao, Haoran
    Zhang, Weijie
    Wang, Jiaqi
    Liu, Yuhong
    Cao, Yuanxiong
    Zheng, Honghui
    Hu, Zhiwei
    Wang, Shubin
    Zhu, Yu
    Wang, Wei
    Cui, Shuzhong
    Lobie, Peter E.
    Huang, Laiqiang
    Ma, Shaohua
    [J]. CELL REPORTS MEDICINE, 2020, 1 (09)
  • [29] Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response
    Feijtel, Danny
    Doeswijk, Gabriela N.
    Verkaik, Nicole S.
    Haeck, Joost C.
    Chicco, Daniela
    Angotti, Carmelina
    Konijnenberg, Mark W.
    de Jong, Marion
    Nonnekens, Julie
    [J]. THERANOSTICS, 2021, 11 (02): : 491 - 505
  • [30] BREAST CANCER INTRA-TUMOR HETEROGENEITY: ONE TUMOR, DIFFERENT ENTITIES
    Esparza-Lopez, Jose
    Escobar-Arriaga, Elizabeth
    Soto-Germes, Santos
    De Jesus Ibarra-Sanchez, Maria
    [J]. REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2017, 69 (02): : 66 - 76